Watson Pharmaceuticals announced that the holding subsidiary Chengdu Huasen Aorui Pharmaceutical Co., Ltd. received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration for ORIC-1327 phosphate eye drops corresponding to 2 indications and 6 specifications. This drug is a new class 1.1 drug. The indications are glaucoma and ocular hypertension. It was independently developed by Watson Auray. ORIC-1327 phosphate eye drops are the second Class 1.1 new drug project approved for clinical use. As of the disclosure date of this announcement, the company's subsidiary Chongqing Huasen Yingnuo Biotechnology Co., Ltd. and Watson Aorui have obtained clinical approvals for three Class 1.1 new drug projects.

Watson Pharmaceuticals announced that the holding subsidiary Chengdu Huasen Aorui Pharmaceutical Co., Ltd. received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration for ORIC-1327 phosphate eye drops corresponding to 2 indications and 6 specifications. This drug is a new class 1.1 drug. The indications are glaucoma and ocular hypertension. It was independently developed by Watson Auray. ORIC-1327 phosphate eye drops are the second Class 1.1 new drug project approved for clinical use. As of the disclosure date of this announcement, the company's subsidiary Chongqing Huasen Yingnuo Biotechnology Co., Ltd. and Watson Aorui have obtained clinical approvals for three Class 1.1 new drug projects.